Abstract

Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years. Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.
Original languageEnglish
Article number371
JournalFrontiers in Behavioral Neuroscience
Volume11
DOIs
Publication statusPublished - 2018

Cite this

@article{89d698efc8fe499a830706b68d2e0aaf,
title = "No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients",
abstract = "Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years. Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.",
author = "Claire Bridel and Eijlers, {Anand J. C.} and {van Wieringen}, {Wessel N.} and Marleen Koel-Simmelink and Leurs, {Cyra E.} and Schoonheim, {Menno M.} and Joep Killestein and Teunissen, {Charlotte E.}",
year = "2018",
doi = "10.3389/fnmol.2018.00371",
language = "English",
volume = "11",
journal = "Frontiers in Behavioral Neuroscience",
issn = "1662-5153",
publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients

AU - Bridel, Claire

AU - Eijlers, Anand J. C.

AU - van Wieringen, Wessel N.

AU - Koel-Simmelink, Marleen

AU - Leurs, Cyra E.

AU - Schoonheim, Menno M.

AU - Killestein, Joep

AU - Teunissen, Charlotte E.

PY - 2018

Y1 - 2018

N2 - Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years. Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.

AB - Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years. Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85056709022&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30429773

U2 - 10.3389/fnmol.2018.00371

DO - 10.3389/fnmol.2018.00371

M3 - Article

VL - 11

JO - Frontiers in Behavioral Neuroscience

JF - Frontiers in Behavioral Neuroscience

SN - 1662-5153

M1 - 371

ER -